Myriad Genetics partnered with actress Jackie Tohn to raise awareness about hereditary cancer testing using the MyRisk Hereditary Cancer Test. Tohn discovered she carried a BRCA1 gene variant linked to high risks of breast and ovarian cancer, leading her to undergo preventive surgeries. The test evaluates genetic risk for 11 cancer types and helps individuals and doctors create personalized health plans. This collaboration highlights the importance of genetic screening, especially for those with family cancer history or Ashkenazi Jewish ancestry.
SaintQuant has officially launched its AI-driven quantitative crypto trading platform, offering retail investors easy, no-code access to automated trading strategies. This launch coincides with Bitcoin surpassing $82,000 and record institutional infl...
SpaceX is expected to release its IPO prospectus soon, aiming to raise $70-75 billion and seek a valuation around $1.75 trillion, which would make it one of the most valuable public companies globally. The company's revenue is largely driven by Starl...
The global protective films market is projected to grow from $5.81 billion in 2026 to $7.62 billion by 2031, at a CAGR of 5.6%. Growth is fueled by rising demand for surface protection during manufacturing, transportation, and installation, especiall...
IDenta Corp reported its strongest quarter ever in Q1 2026, with revenues rising to $520,983 from $174,799 in Q1 2025. The company saw significant profit improvements, turning a net loss into a net profit of $29,860. Growth was driven by expanding in...
Auddia Inc. filed an S-4 registration statement with the SEC for its planned merger with Thramann Holdings, which will form McCarthy Finney, managing four AI-focused businesses. The merger is backed by a $12 million financing and awaits SEC review, s...
